| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/ECC.12761 |
| P698 | PubMed publication ID | 28940410 |
| P50 | author | Maria Gavriatopoulou | Q88776018 |
| Evangelos Terpos | Q57015797 | ||
| P2093 | author name string | M A Dimopoulos | |
| D Christoulas | |||
| P2860 | cites work | Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties | Q21999072 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| The amazing osteocyte | Q24635849 | ||
| A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma | Q24646864 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Apoptotic osteocytes and the control of targeted bone resorption | Q27023670 | ||
| LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development | Q28206790 | ||
| High bone density due to a mutation in LDL-receptor-related protein 5 | Q28217891 | ||
| The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth | Q28473419 | ||
| Down-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma | Q28487775 | ||
| Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation | Q28505419 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Secreted antagonists of the Wnt signalling pathway | Q29615521 | ||
| Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand | Q30670375 | ||
| Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study | Q33503487 | ||
| Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells | Q33803260 | ||
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
| Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma | Q33856318 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Sclerostin: current knowledge and future perspectives | Q33992612 | ||
| Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease | Q34182154 | ||
| Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo | Q34224284 | ||
| Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin | Q42174982 | ||
| Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in | Q42475617 | ||
| Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland | Q42510726 | ||
| Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity | Q43883711 | ||
| Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index | Q44032751 | ||
| Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells | Q44265469 | ||
| Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells | Q44364932 | ||
| Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors | Q44561312 | ||
| Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. | Q44774590 | ||
| CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth | Q45865478 | ||
| The activin A-follistatin system: potent regulator of human extracellular matrix mineralization | Q46280045 | ||
| Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. | Q46283393 | ||
| Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth | Q47141750 | ||
| Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion | Q47371978 | ||
| Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. | Q48020559 | ||
| Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease | Q48022318 | ||
| Romosozumab in postmenopausal women with low bone mineral density. | Q50481558 | ||
| Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. | Q51067506 | ||
| EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. | Q51170659 | ||
| Differentiation of mesenchymal stem cells into osteoblasts on honeycomb collagen scaffolds. | Q51238290 | ||
| Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. | Q52919769 | ||
| Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. | Q53132270 | ||
| Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. | Q53142665 | ||
| Activin A is an essential cofactor for osteoclast induction. | Q54064333 | ||
| Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. | Q54799542 | ||
| Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells | Q56453539 | ||
| Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma | Q57904843 | ||
| Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation | Q57904871 | ||
| Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS) | Q57904962 | ||
| Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma | Q34225092 | ||
| Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator | Q34323936 | ||
| Receptor Activator of NF-κB (RANK) Cytoplasmic IVVY535–538 Motif Plays an Essential Role in Tumor Necrosis Factor-α (TNF)-mediated Osteoclastogenesis | Q34333628 | ||
| Expression and secretion of activin A: possible physiological and clinical implications | Q34343435 | ||
| Sotatercept in patients with osteolytic lesions of multiple myeloma. | Q35035011 | ||
| Review of 1027 patients with newly diagnosed multiple myeloma | Q35045634 | ||
| Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease | Q35631319 | ||
| Pathogenesis of myeloma bone disease | Q35683616 | ||
| Wnt signaling in osteoblasts and bone diseases | Q35913119 | ||
| Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 | ||
| Microdamage and apoptosis | Q36241018 | ||
| Osteocyte RANKL: new insights into the control of bone remodeling | Q36253514 | ||
| The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions | Q36501937 | ||
| Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. | Q36569101 | ||
| Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma | Q36732811 | ||
| The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell | Q36979047 | ||
| Dickkopf-1: a suitable target for the management of myeloma bone disease. | Q37521086 | ||
| Osteocyte-driven bone remodeling | Q37626024 | ||
| Pathogenesis and management of myeloma bone disease | Q37810077 | ||
| The regulation and functions of activin and follistatin in inflammation and immunity. | Q37847437 | ||
| Expanding TRAF function: TRAF3 as a tri-faced immune regulator | Q37887494 | ||
| The effects of bortezomib on bone disease in patients with multiple myeloma | Q38163937 | ||
| Management of bone disease in multiple myeloma | Q38179039 | ||
| Oncogenic roles of EMT-inducing transcription factors | Q38215948 | ||
| Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts | Q38314616 | ||
| Myeloma cells suppress osteoblasts through sclerostin secretion | Q38323256 | ||
| Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation | Q38325516 | ||
| The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors | Q38820789 | ||
| Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone | Q39116021 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma | Q39758292 | ||
| Changes in extracellular activin A:follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes | Q40130858 | ||
| An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma | Q40202882 | ||
| Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro | Q40307786 | ||
| IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma | Q40425654 | ||
| Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. | Q40449381 | ||
| Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment | Q40486816 | ||
| IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells | Q40616669 | ||
| Myeloma affects both the growth and function of human osteoblast-like cells | Q41644573 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-09-21 | |
| P1433 | published in | European Journal of Cancer Care | Q5412710 |
| P1476 | title | Mechanisms of bone destruction in multiple myeloma | |
| P478 | volume | 26 |
| Q50142573 | Bone health in cancer patients - An important clinical issue |
| Q89694000 | Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma |
| Q89529241 | Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells |
| Q100559090 | Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23 |
| Q48194383 | Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion |
| Q64099069 | The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) |
| Q64071253 | Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma |
| Q90418911 | Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI |
Search more.